ClinicalTrials.gg
RecruitingNCT06250491H-FINEPUpdated Mar 27, 2026

Deep rTMS (H-coil) for Neuropathic Pain or Fibromyalgia

An interventional study of Deep active rTMS with Hesed coil and Sham rTMS with Hesed coil in Neuropathic Pain and Fibromyalgia, sponsored by Nadine ATTAL. Recruiting at 2 sites in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Nadine ATTAL · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 132 studies in Neuralgia with a site in France — 39 open to participants now, 40 under way, 4 of them phase 3. Neuralgia · France.

Planned enrollment
42nd of 102
70 · median 62
Started
2024
with 9 others
No phase
46 of 132
23 open now
Primary completion
2027-01
later than 11 of 39 live
Registered
108th of 132
by date

Among the 132 studies in Neuralgia with a site in France, this one is the 42nd largest by planned enrollment of the 102 interventional ones that give a count, is one of 10 that started in 2024, is one of 46 with no phase, reaches primary completion later than 11 of the 39 other live ones, and was the 108th registered.

Neuralgia

1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.

Browse Neuralgia studies →

Open to participants now

39 of the 132 studies in Neuralgia with a site in France are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 155 Neuralgia studies recruiting now, 79 (51%) set no upper age limit and 44 (28%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies in Neuralgia with a site in France, or all of them as a file.
02

Study summary

This study will investigate the efficacy and safety of "deep" rTMS on neuropathic pain or fibromyalgia. It will be randomized and sham controlled and will last 3 months. Patients will be randomized to receive acctive rTMS or sham rTMS and will receive repeated rTMS sessions (5 daily sessions then one session per week then every 2 to 3 weeks for up to 10 weeks).

Read the detailed description

This double blind sham controlled parallel group bicenter study will assess the efficacy and safety of repeated sessions of deep rTMS using H coil in patients with neuropathic pain or fibromyalgia. Primary outcome will be % of pain relief at week 13.

03

Conditions studied

  • Neuropathic Pain
  • Fibromyalgia

Keywords

  • Neuropathic pain - Fibromyalgia - deep rTMS
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic pain ≥ 6 months, at least 4/10 on a 0-10 NRS, present every day or nearly every day
  • Neuropathic pain (confirmed with Douleur Neuropathique en 4 questions and international criteria from NeuPSIG) or fibromyalgia (revised ACR criteria)
  • Stable concomitant medications for pain for at least one month
  • Able to fill out questionnaires and understand and speak French

Exclusion criteria

Exclusion Criteria:

  • to rTMS
  • Prior treatment with rTMS
  • Progressive severe condition (eg cancer)
  • Psychosis
  • Psychoactive drug abuse
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Active rTMS

    Deep rTMS with H coil targeting the motor cortex bilaterally

    Device: Deep active rTMS with Hesed coil · Device: Sham rTMS with Hesed coil

  • Placebo comparator
    Sham rTMS

    Sham rTMS with H coil targeting the motor cortex bilaterally

    Device: Deep active rTMS with Hesed coil · Device: Sham rTMS with Hesed coil

Interventions

  • DeviceDeep active rTMS with Hesed coil

    This brain neurostimulation method targets the motor cortex bilaterally

  • DeviceSham rTMS with Hesed coil

    This brain sham neurostimulation method targets the motor cortex bilaterally

06

What researchers measure

Primary outcomes

  1. Effects of rTMS versus sham rTMS on pain relief at 13 weeks

    Pain relief scale from the Brief Pain Inventory rated from 0 to 100 %

    Time frame: 13 weeks

Secondary outcomes

  1. Effects of rTMS vs sham on average pain intensity

    Average pain intensity from the Brief Pain Inventory rated from 0 to 10 on a 0-10 numerical pain scale

    Time frame: Each follow up visit at the pain center for up to 13 weeks

  2. Effects of rTMS vs sham on pain interference

    pain interference from Brief Pain Inventory rated from 0 to 70 (total score)

    Time frame: Baseline then each follow up visit at the pain center for up to 13 weeks

  3. Effects of rTMS vs sham on quality of life

    Euroqol scale which includes 5 dimensions of quality of life and a 0-100 visual analog scale

    Time frame: Baseline then each follow up vist at the pain center for up to 13 weeks

  4. Side effects of rTMS or sham

    Any side effects reported by the patients assessed at each visit after each treatment session and rated as mild, moderate or severe

    Time frame: Each follow up visit at the pain center for up to 13 weeks

  5. Comparison of the efficacy of rTMS on the primary outcome between patients with neuropathic pain and fibromyalgia

    Comparison of both populations on the pain relief scale from the Brief Pain Inventory (0-100 %)

    Time frame: Week 13

  6. Blinding assessment

    Blindinq questionnaire at 13 weeks(end of the study)

    Time frame: 13 weeks

  7. Patient global impression of change

    Patient global impression of change at 13 weeks (from much improved to much deteriorated)

    Time frame: 13 weeks

  8. Self-reported pain intensity

    Average pain intensity from past 24 hours based on 0-10 numerical pain scale

    Time frame: Baseline then every day at the same time of day (morning or evening)

  9. Effects of rTMS versus sham on anxiety and depressive symptoms

    Anxiety and depressive symptoms of the Hospital Anxiety and Depressive scale rated from 0 to 21 for anxiety and 0 to 21 for depression

    Time frame: Baseline then each follow up visit at the pain center for up to 13 weeks

  10. Effects of rTMS vs sham on pain as its worst from Brief Pain Inventory

    pain intensity on 0-10 numerical rating scale

    Time frame: Baseline then each follow up visit at the pain center for up to 13 weeks

  11. Effects of rTMS vs sham on pain as its least from Brief Pain Inventory

    pain intensiy on 0-10 numerical rating scale

    Time frame: Baseline then each follow up visit at the pain center for up to 13 weeks

  12. Effects of rTMS vs sham on sleep

    Sleep assessed using the sleep scale from the Medical Outcome Survey

    Time frame: Baseline then each follow up visit at the pain center for up to 13 weeks

  13. Effects of rTMS vs sham on pain right now from Brief Pain Inventory

    pain intensiy on 0-10 numerical rating scale

    Time frame: Baseline then each follow up visit at the pain center for up to 13 weeks

  14. Effects on Global Impression of change assessed by the clinician

    Clinician global impression of change (from much improved to much deteriorated)

    Time frame: 13 weeks (end of the treatment)

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jan 2027, 36 months after the start.

Of 249 non-industry interventional studies with no phase under Neuralgia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's planned 36 months is above that.

Counting every sponsor, half of 267 studies reached it within 24 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2024
First posted
Feb 9, 2024
StartActual
Jan 30, 2024
Primary completionEst.
Jan 30, 2027
CompletionEst.
Apr 30, 2027
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06250491
Lead sponsor
Nadine ATTAL
Responsible party
Nadine ATTAL (Clinical Professor, Hospital Ambroise Paré Paris) — Sponsor-investigator
First posted
Feb 9, 2024
Start date
Jan 30, 2024
Primary completion
Jan 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Mar 27, 2026

Study contacts

Nadine ATTAL
Contact
nadine.attal@aphp.fr
0033149095931
Nadine ATTAL
study director · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion